BIOMAT Database Logo BIOMAT Database Logo

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). 1997

R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
Academisch Ziekenhuis Leiden, The Netherlands.

5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia. Sixty-three patients received 5-Aza-2'-deoxycytidine 125 mg/m2 as a 6 h infusion every 12 h for 6 days in combination with either amsacrine 120 mg/m2 as a 1 h infusion on days 6 and 7 (n=30) or idarubicin 12 mg/m2 as a 15 min infusion on days 5, 6 and 7 (n = 33). Twenty-three patients (36.5%) obtained a complete remission (CR); eight of 30 patients treated with amsacrine and 15 of 33 treated with idarubicin. Patients with an interval of more than 1 year between initial diagnosis and start of the protocol achieved CR in 51.4%, compared to 15.4% for patients with an interval of less than 1 year. Patients with normal cytogenetics had a higher CR rate (61%) than those with abnormal cytogenetic findings (15.8%). Digestive tract and hematologic toxicity was prolonged, compared to standard induction schedules. Median disease-free survival was approximately 8 months, with only 20% of patients staying in remission for more than 1 year. 5-Aza-2'-deoxycytidine is a good antileukemic agent with considerable toxicity. Current results merit further investigations in previously untreated leukemia.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077209 Decitabine An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. 2'-Deoxy-5-azacytidine,5-Aza-2'-deoxycytidine,5-AzadC,5-Azadeoxycytidine,5-Deoxyazacytidine,5AzadC,AzadC Compound,Dacogen,Decitabine Mesylate,NSC 127716,NSC-127716,2' Deoxy 5 azacytidine,5 Aza 2' deoxycytidine,5 Azadeoxycytidine,5 Deoxyazacytidine,Compound, AzadC,Mesylate, Decitabine,NSC127716
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
May 1993, Leukemia,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.
January 1981, Leukemia research,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group.
February 1990, European journal of cancer (Oxford, England : 1990),
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
[Early phase II study of Idarubicin combined with cytarabine in acute myelogenous leukemia. Idarubicin Study Group].
May 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
October 2014, Pediatric blood & cancer,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group.
May 1992, Annals of oncology : official journal of the European Society for Medical Oncology,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia.
January 1985, Pharmacology & therapeutics,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia.
December 1989, Bone marrow transplantation,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
[A late phase II study of idarubicin hydrochloride in adult patients with acute lymphocytic leukemia. Idarubicin Study Group].
October 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
R Willemze, and S Suciu, and E Archimbaud, and P Muus, and P Stryckmans, and E A Louwagie, and Z Berneman, and M Tjean, and P Wijermans, and H Dohner, and U Jehn, and B Labar, and B Jaksic, and M Dardenne, and R Zittoun
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
November 2006, Blood,
Copied contents to your clipboard!